How do you reduce off-target transgene expression in gene therapy?

In gene therapy, getting an expressing vector into the target cell is half the problem; keeping it out of the wrong cell is the other half. Reducing off-target expression means selecting a regulatory element that is shown to be silent in the tissues you must avoid, not only active in the target. Most promoter data describes where a sequence is active and says little, with statistical confidence, about where it is not, and that gap is where programs get into trouble.

When working with drug developers, we aim to be transparent that complete transcriptional silence is rarely absolute; much like silence in everyday life, there is often a measurable background signal. Moreover, proving a negative is inherently difficult, which is why de-targeting is often treated as a preference rather than a specification. It does not have to be. By including relevant off-target contexts from the start, either in cultured cells or in vivo models, the absence of activity can be quantified with the same rigor as a desired expression profile. Our customers typically define the off-target tissues that are most relevant for their indication, and we design the screening panel accordingly.

In a SuRE™ screen, candidates are measured against a panel that includes the off-target cell types, and we report the full activity distribution across on- and off-target contexts. You select for a clean specificity profile rather than trusting a nominal label.

A recurring surprise for customers is that elements known in literature for one lineage can drive strong expression in unrelated tissues in vivo. That is why we keep going on about actually measured off-target activity, rather than only the on-target activity known from literature.

The need is sharpest for payloads that are toxic when ending up in the wrong cell, central-nervous-system programs that must spare the dorsal root ganglia (DRG), liver de-targeting for systemically delivered vectors, and in-vivo cell therapies where you cannot select ex vivo engineered cells before administration. All of these topics Annogen has traversed at some point since its start in 2017.

Talk to us. If de-targeting a specific tissue is on your risk list, we are here to take it into our SuRE™ assay for you.